Applied Therapeutics Elects New Director at Annual Meeting

The latest update is out from Applied Therapeutics ( (APLT) ).

At the 2025 Annual Meeting of Stockholders on June 9, 2025, Applied Therapeutics, Inc. elected Teena Lerner, Ph.D., as a Class III director to serve until the 2028 meeting. The stockholders also ratified Ernst & Young LLP as the independent registered public accounting firm for 2025, approved executive compensation, and decided on an annual advisory vote on executive pay. Additionally, an amendment was approved to potentially consolidate the company’s common stock by a ratio of one-for-5 to one-for-40, with the exact ratio to be determined by the board.

The most recent analyst rating on (APLT) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Applied Therapeutics stock, see the APLT Stock Forecast page.

Spark’s Take on APLT Stock

According to Spark, TipRanks’ AI Analyst, APLT is a Underperform.

Applied Therapeutics is in the early stages of revenue generation, but significant challenges in achieving profitability and sustaining operations through negative cash flow pose risks. The technical analysis shows downward momentum, and valuation metrics reflect its current unprofitability. Focus remains on operational improvements and expense management to navigate financial instability.

To see Spark’s full report on APLT stock, click here.

More about Applied Therapeutics

Applied Therapeutics, Inc. operates in the pharmaceutical industry, focusing on developing novel therapeutics for diseases with significant unmet medical needs.

Average Trading Volume: 2,184,100

Technical Sentiment Signal: Sell

Current Market Cap: $54.66M

For an in-depth examination of APLT stock, go to TipRanks’ Stock Analysis page.